VEGFD antibody (Middle Region)
Quick Overview for VEGFD antibody (Middle Region) (ABIN3044291)
Target
See all VEGFD (Figf) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 101-115, Middle Region
-
Purpose
- Anti-VEGFD/FIGF Antibody
-
Sequence
- VIDEEWQRTQ CSPRE
-
Cross-Reactivity (Details)
- No cross-reactivity with other proteins
-
Characteristics
- Anti-VEGFD/FIGF Antibody (ABIN3044291). Tested in IHC, WB applications. This antibody reacts with Human, Mouse, Rat. This is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications.
-
Purification
- Immunogen affinity purified.
-
Immunogen
- A synthetic peptide corresponding to a sequence in the middle region of human VEGFD, identical to the related rat and mouse sequences.
-
Isotype
- IgG
-
-
-
-
Application Notes
-
Immunohistochemistry (Paraffin-embedded Section), 0.5-1 μg/mL, Human, Rat, Mouse
Western blot, 0.1-0.5 μg/mL, Human, Rat, Mouse
-
Comment
-
Antibody can be supported by chemiluminescence kit ABIN921124 in WB, supported by ABIN921231 in IHC(P).
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
-
Concentration
- 500 μg/mL
-
Buffer
- Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Thimerosal, 0.05 mg Sodium azide.
-
Preservative
- Thimerosal (Merthiolate), Sodium azide
-
Precaution of Use
- This product contains Thimerosal (Merthiolate) and Sodium azide: POISONOUS AND HAZARDOUS SUBSTANCES which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
-
Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles. -
Expiry Date
- 12 months
-
-
-
: "VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein." in: International journal of oncology, Vol. 49, Issue 1, pp. 123-32, (2017) (PubMed).
-
: "VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein." in: International journal of oncology, Vol. 49, Issue 1, pp. 123-32, (2017) (PubMed).
-
- VEGFD (Figf) (C-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D) (Figf))
-
Alternative Name
- FIGF
-
Background
-
Synonyms: Vascular endothelial growth factor D,VEGF-D,c-Fos-induced growth factor,FIGF,FIGF,VEGFD,
Tissue Specificity: Highly expressed in lung, heart, small intestine and fetal lung, and at lower levels in skeletal muscle, colon, and pancreas.
Background: C-fos induced growth factor (FIGF) (or vascular endothelial growth factor D, VEGF-D) is a vascular endothelial growth factor that in humans is encoded by the FIGF gene. The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. Analyzing by Northern blotting, Yamada et al. (1997) symbolized VEGFD, was expressed as a 2.2-kb transcript with highest expression in lung, heart, small intestine, and fetal lung, and lower levels in skeletal muscle, colon, and pancreas. And Achen et al. (1998) concluded that VEGFD was most closely related to VEGFC by virtue of the presence of N- and C-terminal extensions that were not found in other VEGF family members. Stacker et al. (2001) showed that VEGFD can induce tumor angiogenesis through VEGFR2 and tumor lymphangiogenesis through VEGFR3, whereas VEGF, which does not activate VEGFR3, induces only tumor angiogenesis.
Sequence Similarities: Belongs to the PDGF/VEGF growth factor family.
-
Molecular Weight
- 160 kDa
-
UniProt
- O43915
-
Pathways
- RTK Signaling
Target
-